We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
HCG (Human Chorionic Gonadotropin) — LH-mimetic gonadotropin
A placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism. Clinical use of hCG depends on the diagnosis and the exact product’s prescribing information. Evidence for adding hCG to testosterone treatment is more limited: a short study measured intratesticular testosterone, not pregnancy or live-birth outcomes. It does not establish that fertility will be preserved during testosterone therapy. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks.
Prescription medication — not a dietary supplement
HCG (Human Chorionic Gonadotropin) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
HCG (Human Chorionic Gonadotropin) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1976–2026 with a typical study size of 51 participants.
Based on 404 studies · 69 meta-analyses · 309 RCTs · 1,715 total participants
Confidence
High confidenceBy outcome
hCG has solid, trial-backed roles on the gonadal axis — a randomized dose-response showing it maintains intratesticular testosterone under TRT, established spermatogenesis induction in hypogonadotropic men, and meta-analysis-level use as the female ovulation trigger — but the TRT-fertility-adjunct use rests on small cohorts, the male-fertility evidence is largely observational, and none of it extends beyond the gonadal axis (no longevity/healthspan benefit), with real OHSS/estradiol risks and grey-market sourcing concerns.
34 trials ongoing or recruiting · 211 completed on ClinicalTrials.gov
50 of the completed trials have posted results
Registered trials show research momentum for HCG (Human Chorionic Gonadotropin), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by the placenta whose beta-subunit closely resembles luteinizing hormone (LH).
It binds and activates the LH/CG receptor (LHCGR) on testicular Leydig cells in men and ovarian theca/granulosa cells in women, where it acts as a long-acting LH analogue — its much longer circulating half-life than native LH is exactly why it is therapeutically useful.
It is a prescription drug (urinary-derived as Pregnyl/Novarel, or recombinant choriogonadotropin alfa as Ovidrel/r-hCG), not a dietary supplement. The human evidence clusters around gonadal-axis uses.
First, female fertility: hCG is the standard agent to trigger final oocyte maturation and ovulation in induction and assisted-reproduction (IVF/IUI) cycles, where a single dose mimics the natural mid-cycle LH surge — recombinant and urinary hCG produce comparable outcomes, and hCG remains the reference 'trigger' against which newer dual-trigger protocols are compared.
Second, male fertility induction: in men with hypogonadotropic hypogonadism, hCG stimulates Leydig-cell testosterone production and (alone in post-pubertally acquired/adult-onset cases with adequate testicular volume, or combined with FSH in congenital cases such as Kallmann syndrome) induces spermatogenesis, with success predicted by baseline testicular volume, inhibin B, and absence of prior cryptorchidism.
A three-week mechanistic study examined intratesticular testosterone with hCG during testosterone administration. A separate small retrospective cohort reported semen outcomes with 500 IU hCG every other day. These designs and regimens must not be merged into a proven fertility-preserving treatment.
Clinical use of hCG depends on the diagnosis and the exact product’s prescribing information. Evidence for adding hCG to testosterone treatment is more limited: a short study measured intratesticular testosterone, not pregnancy or live-birth outcomes.
It does not establish that fertility will be preserved during testosterone therapy. The honest scope: hCG's benefits are confined to the gonadal (hypothalamic-pituitary-gonadal) axis — fertility, intratesticular testosterone, and Leydig-cell steroidogenesis.
It is NOT a longevity or healthspan drug, has no demonstrated systemic anti-aging benefit, and the once-popular 'hCG diet' for weight loss is discredited.
As a prescription gonadotropin it also carries real risks — ovarian hyperstimulation syndrome in women, gynecomastia/estradiol elevation and testicular discomfort in men — and grey-market or compounded products marketed for TRT or bodybuilding may, on top of the pharmacology, have unreliable identity, strength or quality.
hCG's beta-subunit mimics LH; it binds and activates the LH/CG receptor (LHCGR) on testicular Leydig cells in men and ovarian theca/granulosa cells in women — acting as a long-acting LH analogue with a far longer half-life than native LH.
Receptor activation on Leydig cells stimulates testosterone synthesis. Intratesticular testosterone (ITT) is ~50-100× higher than serum testosterone and is required for spermatogenesis; hCG sustains ITT even when pituitary LH/FSH are suppressed by exogenous testosterone.
In men, sustained Leydig-cell ITT (often with FSH) supports Sertoli-cell-driven spermatogenesis. In women, a single hCG dose mimics the mid-cycle LH surge to trigger final oocyte maturation and ovulation — provided the gonads are responsive.
How HCG (Human Chorionic Gonadotropin) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Small studies have examined hCG with testosterone, but they do not establish reliable preservation of fertility during testosterone treatment. A fertility specialist should assess the indication, alternatives and monitoring before treatment.
An evidence-backed indication — hCG (alone or with FSH) induces spermatogenesis; congenital/Kallmann cases generally need combined hCG+FSH. Specialist-managed.
hCG is a standard trigger but carries OHSS risk; must be used with cycle monitoring under a fertility specialist.
Avoid — stimulating sex-steroid production could be harmful; specialist input required.
Avoid unverified sources: products from unverified sources may have unreliable identity, strength or quality. Obtain prescription product through legitimate channels.
Exogenous androgens suppress LH/FSH and intratesticular testosterone; the rationale for adding hCG is to maintain Leydig-cell function and fertility. This use is real but largely off-label and supported mainly by small cohorts; it can also raise estradiol.
Frequently combined with hCG to induce spermatogenesis (men) or follicular development (women); appropriate but increases ovarian-hyperstimulation risk in women and requires monitoring.
Sometimes co-prescribed to blunt the estradiol rise hCG can cause in men; alters the estrogen/androgen balance and should be clinician-managed.
These suppress endogenous gonadotropins; co-use changes the hormonal context and should only be combined under specialist protocols (e.g. assisted reproduction).
Tip: Rotate sites; recombinant hCG tends to cause fewer local reactions than urinary product
Tip: Monitor estradiol; an aromatase inhibitor may be added under clinician guidance
Tip: Dose-related; monitor follicles by ultrasound and estradiol, and avoid/withhold the trigger in high-response cycles
Tip: Usually dose-related and reversible; adjust dose with the prescriber
Tip: Usually transient
HCG (Human Chorionic Gonadotropin) has an evidence score of 5.5/10 — moderate evidence based on 408 indexed studies, including 1 meta-analysis. A placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism. Clinical use of hCG depends on the diagnosis and the exact product’s prescribing information. Evidence for adding hCG to testosterone treatment is more limited: a short study measured intratesticular testosterone, not pregnancy or live-birth outcomes. It does not establish that fertility will be preserved during testosterone therapy. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks. Representative study: PMID 37466846.
Dosing for HCG (Human Chorionic Gonadotropin): Prescription-only and indication-dependent. For intratesticular-testosterone maintenance on TRT, the cited studies used 125-500 IU every other day (intramuscular in the one that states the route). For spermatogenesis induction in hypogonadotropic hypogonadism, typically ~1,000-2,500 IU two to three times weekly (often combined with FSH), titrated to response. For female ovulation/oocyte-maturation trigger, a single dose (~5,000-10,000 IU urinary or 250 µg recombinant). No cited study gives these two doses. No dietary-supplement dose exists. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for HCG (Human Chorionic Gonadotropin) — consistent daily use matters more than the time of day. Dosing is by indication, not a daily supplement schedule: every-other-day low doses for intratesticular-testosterone maintenance, two-to-three-times-weekly for spermatogenesis induction, and a single timed trigger dose for ovulation.
HCG (Human Chorionic Gonadotropin) should be used with caution — talk to a healthcare provider before taking it. Reported side effects include ovarian hyperstimulation syndrome (women), injection-site reaction (pain, redness, swelling), estradiol elevation / gynecomastia / water retention (men), testicular discomfort / mood or libido changes (men). How often they occur is not established for all of them. Use caution if any of these apply to you: Hormone-sensitive tumors (e.g. prostate, breast) or other androgen/estrogen-dependent conditions; Known hypersensitivity to hCG; Use without medical supervision.
What side effects does HCG (Human Chorionic Gonadotropin) have?Don't take this if…
Enclomiphene
Too few graded studiesThe trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used investigationally as a testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone. Honest appraisal: Phase-2/3 RCTs show it raises testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality).
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Explore: Best supplements for Women's HealthBest supplements for Men's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 408 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research